Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects \>15months to \<18years in good health, available for entire study period and reachable by phone, parents/legal guardian able and willing to complete all study procedures, written documentation from health professional showing prior vaccination with Prevnar (except for group 4).~Group 4 only:~* Negative urine pregnancy test for female subjects who are menstruating.~Exclusion Criteria:~* Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component , bleeding diathesis, received blood transfusion or blood related products, immune deficiency,congenital malformation.~Group 4 only:~* Previous vaccination with Prevnar or any other pneumococcal vaccine.~* Pregnant or breastfeeding adolescent females.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Single (Type: EXPERIMENTAL): Open label

Based on this trial design, predict the completion outcome and termination type (if applicable).